CEO Eliot Forster leaves Im­muno­core as the UK biotech uni­corn hunts cash

High pro­file UK biotech ex­ec Eliot Forster has stepped down as CEO from Im­muno­core, the T cell re­cep­tor biotech he’s led to star sta­tus in the three years he was at the helm.

Un­der Forster’s lead­er­ship, Im­muno­core raised a record-break­ing $320 mil­lion Se­ries A — stun­ning not just in Eu­rope but even the US, where on­ly Mod­er­na has topped that — as well as seal­ing part­ner­ships with As­traZeneca, Glax­o­SmithK­line and Roche. While the com­pa­ny is main­ly known for its next-gen can­cer ther­a­pies, the on­go­ing sec­ond fund­ing round has at­tract­ed in­vest­ment from the Gates Foun­da­tion, which com­mit­ted $40 mil­lion to HIV and tu­ber­cu­lo­sis R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER